TY  - GEN
AU  - Bortolotti,Massimo
AU  - Polito,Letizia
AU  - Bolognesi,Andrea
AU  - Bortolotti,Massimo
AU  - Polito,Letizia
AU  - Bolognesi,Andrea
TI  - Toxin and Immunotoxin Based Therapeutic Approaches
SN  - books978-3-0365-3065-9
PY  - 2022///
CY  - Basel
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Humanities
KW  - bicssc
KW  - Social interaction
KW  - 3D structure
KW  - plant toxin
KW  - primary sequence
KW  - ribosome-inactivating protein
KW  - stenodactylin
KW  - toxic lectin
KW  - fusion proteins
KW  - ricin
KW  - pokeweed antiviral protein
KW  - COVID-19
KW  - SARS-CoV-2
KW  - antiviral agent
KW  - ribosome-inactivating proteins
KW  - monoclonal antibody
KW  - immunotoxin
KW  - antibody drug conjugate
KW  - immunoliposome
KW  - drug delivery
KW  - diphtheria toxin
KW  - DT3C
KW  - prostate cancer
KW  - targeted toxins
KW  - epidermal growth factor
KW  - epidermal growth factor receptor
KW  - Pseudomonas Exotoxin A
KW  - patient-derived glioblastoma cell lines
KW  - Chenopodium quinoa wild
KW  - quinoin
KW  - temozolomide
KW  - Glypican-3
KW  - hepatocellular carcinoma
KW  - humanized YP7
KW  - new recombinant immunotoxin
KW  - kirkiin
KW  - sugar specificity
KW  - cancer therapy
KW  - n/a
N1  - Open Access
N2  - In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments.   A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity.   This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo
UR  - https://mdpi.com/books/pdfview/book/4929
UR  - https://directory.doabooks.org/handle/20.500.12854/78835
ER  -